Published in J Gynecol Oncol on December 31, 2010
Sirtuin activators and inhibitors. Biofactors (2012) 1.19
Sirtuin inhibitors as anticancer agents. Future Med Chem (2014) 0.98
Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther (2014) 0.90
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett (2012) 0.86
Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenetics (2016) 0.80
Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One (2012) 0.80
Treatment of etoposide combined with 15-deoxy-Δ(12,14)-prostaglandin J2 exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator-activated receptor-γ-independent pathways. Mol Clin Oncol (2013) 0.79
Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation. PLoS One (2013) 0.79
Lysophosphatidic Acid Inhibits Apoptosis Induced by Cisplatin in Cervical Cancer Cells. Biomed Res Int (2015) 0.77
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer (2016) 0.75
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells. J Cancer (2017) 0.75
Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget (2016) 0.75
Role of SIRT1-mediated mitochondrial and Akt pathways in glioblastoma cell death induced by Cotinus coggygria flavonoid nanoliposomes. Int J Nanomedicine (2015) 0.75
The language of covalent histone modifications. Nature (2000) 44.92
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Histone acetylation in chromatin structure and transcription. Nature (1997) 14.64
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell (1993) 10.83
Histone acetylation and transcriptional regulatory mechanisms. Genes Dev (1998) 10.16
Histone acetyltransferases. Annu Rev Biochem (2001) 10.00
Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12
A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell (1993) 6.13
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J (1998) 5.28
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
Glutathione metabolism and its selective modification. J Biol Chem (1988) 4.89
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res (2000) 3.83
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.66
Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J (1999) 3.51
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Functional significance of histone deacetylase diversity. Curr Opin Genet Dev (2001) 2.79
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact (1998) 2.55
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res (2001) 2.25
Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev (2001) 2.14
Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem (1993) 2.12
BCL-2 and glutathione: alterations in cellular redox state that regulate apoptosis sensitivity. Free Radic Biol Med (1999) 1.95
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol (2005) 1.66
Bax can antagonize Bcl-XL during etoposide and cisplatin-induced cell death independently of its heterodimerization with Bcl-XL. J Biol Chem (1996) 1.53
Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res (2005) 1.50
Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis (2008) 1.37
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest (1986) 1.35
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther (2004) 1.22
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol Pharmacol (2005) 1.21
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta (2004) 1.12
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer (2002) 1.08
Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer (1998) 1.08
Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene (1998) 0.98
Glutathione and drug resistance. Cancer Invest (1996) 0.95
Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit Rev Toxicol (2005) 0.92
Effect of mycorrhization on the accumulation of rishitin and solavetivone in potato plantlets challenged with Rhizoctonia solani. Mycorrhiza (2003) 0.91
Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32. Chemotherapy (2000) 0.84
Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2. J Urol (1999) 0.81
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol (2011) 2.76
Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol (2008) 1.89
Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center. Gynecol Oncol (2007) 1.81
Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol (2012) 1.49
Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol (2007) 1.23
Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol (2008) 1.09
Surgical management of borderline ovarian tumors: The role of fertility-sparing surgery. Gynecol Oncol (2009) 1.06
Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol (2008) 1.06
Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol (2008) 1.05
Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol (2008) 1.04
The impact of tumor morcellation during surgery on the outcomes of patients with apparently early low-grade endometrial stromal sarcoma of the uterus. Ann Surg Oncol (2011) 1.03
Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol (2013) 1.02
Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry (2004) 1.02
Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene (2005) 1.01
Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. J Gynecol Oncol (2008) 0.99
Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors? Gynecol Oncol (2006) 0.98
Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol Cancer Ther (2002) 0.97
Further stratification of risk groups in patients with lymph node metastasis after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol (2010) 0.97
Fertility-sparing surgery for young women with early-stage epithelial ovarian cancer. Gynecol Obstet Invest (2013) 0.96
The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol (2012) 0.96
Menthol regulates TRPM8-independent processes in PC-3 prostate cancer cells. Biochim Biophys Acta (2008) 0.96
Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports. Jpn J Clin Oncol (2010) 0.95
Laparoscopic versus open radical hysterectomy in patients with stage IB2 and IIA2 cervical cancer. J Surg Oncol (2013) 0.94
Vaginal cuff dehiscence after hysterectomy. Int J Gynaecol Obstet (2013) 0.94
Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer. Ann Surg Oncol (2008) 0.94
Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest (2011) 0.94
Differential gene expression profiling in human cholangiocarcinoma cells treated with Clonorchis sinensis excretory-secretory products. Parasitol Res (2008) 0.93
Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary. Gynecol Oncol (2011) 0.93
Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. J Gynecol Oncol (2012) 0.93
High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys (2009) 0.92
Primary yolk sac tumor of the omentum: a case report and review of the literature. Arch Gynecol Obstet (2008) 0.92
Update on treatment of uterine sarcoma. Curr Opin Obstet Gynecol (2010) 0.92
Clinical significance of tumor volume in endometrial cancer: a Japan-Korea cooperative study. Gynecol Oncol (2013) 0.91
Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer (2010) 0.91
Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J Korean Med Sci (2010) 0.91
Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study. J Clin Oncol (2012) 0.91
A low-risk group for lymph node metastasis is accurately identified by Korean gynecologic oncology group criteria in two Japanese cohorts with endometrial cancer. Gynecol Oncol (2013) 0.91
Laparoscopic versus open radical hysterectomy for elderly patients with early-stage cervical cancer. Am J Obstet Gynecol (2012) 0.90
Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol (2013) 0.90
Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J Gynecol Oncol (2009) 0.89
The efficacy of conservative management after conization in patients with stage IA1 microinvasive cervical carcinoma. Acta Obstet Gynecol Scand (2009) 0.89
Surgical practice patterns in endometrial cancer: results of the Korean Gynecologic Oncology Group survey. J Gynecol Oncol (2009) 0.89
Clinical presentation of endometrioid epithelial ovarian cancer with concurrent endometriosis: a multicenter retrospective study. Cancer Epidemiol Biomarkers Prev (2010) 0.88
Long-term outcomes after fertility-sparing laparoscopic radical trachelectomy in young women with early-stage cervical cancer: an Asan Gynecologic Cancer Group (AGCG) study. J Surg Oncol (2014) 0.88
Pure primary squamous cell carcinoma of the ovary: a report of two cases and review of the literature. Int J Gynecol Pathol (2010) 0.86
Role of PET or PET/CT in the post-therapy surveillance of uterine sarcoma. Gynecol Oncol (2008) 0.86
Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer (2012) 0.86
The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol (2010) 0.85
Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy. Tumori (2011) 0.85
Yeast cells lacking the CIT1-encoded mitochondrial citrate synthase are hypersusceptible to heat- or aging-induced apoptosis. Mol Biol Cell (2007) 0.85
The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. J Gynecol Oncol (2012) 0.85
Endometrial stromal tumor with limited infiltration and probable extrauterine metastasis: report of a case. Ann Diagn Pathol (2005) 0.85
Progression-free survival is accurately predicted in patients treated with chemotherapy for epithelial ovarian cancer by the histoculture drug response assay in a prospective correlative clinical trial at a single institution. Anticancer Res (2013) 0.85
Proliferation of CD4CD25Foxp3 regulatory T lymphocytes in ex vivo expanded ascitic fluid from primary and recurrent ovarian carcinoma. J Gynecol Oncol (2010) 0.85
Prognostic factors in women with synchronous endometrial and ovarian cancers. Int J Gynecol Cancer (2014) 0.85
Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand (2010) 0.84
Micropapillary pattern in serous borderline ovarian tumors: does it matter? Gynecol Oncol (2011) 0.84